D F Ackerley
Overview
Explore the profile of D F Ackerley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
326
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Copp J, Williams E, Rich M, Patterson A, Smaill J, Ackerley D
Protein Eng Des Sel
. 2014 Jul;
27(10):399-403.
PMID: 24996412
Engineering of enzymes to more efficiently activate genotoxic prodrugs holds great potential for improving anticancer gene or antibody therapies. We report the development of a new, GFP-based, high-throughput screening platform...
2.
Swe P, Copp J, Green L, Guise C, Mowday A, Smaill J, et al.
Biochem Pharmacol
. 2012 Jul;
84(6):775-83.
PMID: 22796568
Phase I/II cancer gene therapy trials of the Escherichia coli nitroreductase NfsB in partnership with the prodrug CB1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide] have indicated that CB1954 toxicity is dose-limiting at concentrations far below...
3.
OWEN J, Robins K, Parachin N, Ackerley D
Environ Microbiol
. 2012 Feb;
14(5):1198-209.
PMID: 22356582
The single-module non-ribosomal peptide synthetase BpsA from Streptomyces lavendulae has the unique ability to autonomously synthesize a coloured product (indigoidine) from a single substrate (l-glutamine), conditional upon activation by a...
4.
Prosser G, Patterson A, Ackerley D
J Biotechnol
. 2010 Aug;
150(1):190-4.
PMID: 20727918
CB1954 is an anti-cancer prodrug that can be reduced at either of two nitro groups to form cytotoxic metabolites. We describe here two efficient and previously uncharacterized nitroreductases, YfkO from...
5.
Prosser G, Copp J, Syddall S, Williams E, Smaill J, Wilson W, et al.
Biochem Pharmacol
. 2009 Oct;
79(5):678-87.
PMID: 19852945
Gene-directed enzyme prodrug therapy (GDEPT) aims to achieve highly selective tumor-cell killing through the use of tumor-tropic gene delivery vectors coupled with systemic administration of otherwise inert prodrugs. Nitroaromatic prodrugs...
6.
Lynch S, Dixon L, Benoit M, Brodie E, Keyhan M, Hu P, et al.
Antimicrob Agents Chemother
. 2007 Aug;
51(10):3650-8.
PMID: 17664315
By using a high-throughput screening method, a mutant of a uropathogenic Escherichia coli strain affected in the rapA gene was isolated. The mutant formed normal-architecture biofilms but showed decreased penicillin...
7.
Barak Y, Ackerley D, Dodge C, Banwari L, Alex C, Francis A, et al.
Appl Environ Microbiol
. 2006 Nov;
72(11):7074-82.
PMID: 17088379
Most polluted sites contain mixed waste. This is especially true of the U.S. Department of Energy (DOE) waste sites which hold a complex mixture of heavy metals, radionuclides, and organic...
8.
Ackerley D, Barak Y, Lynch S, Curtin J, Matin A
J Bacteriol
. 2006 Apr;
188(9):3371-81.
PMID: 16621832
The nature of the stress experienced by Escherichia coli K-12 exposed to chromate, and mechanisms that may enable cells to withstand this stress, were examined. Cells that had been preadapted...
9.
Ackerley D, Gonzalez C, Keyhan M, Blake 2nd R, Matin A
Environ Microbiol
. 2004 Jul;
6(8):851-60.
PMID: 15250887
Chromate [Cr(VI)] is a serious environmental pollutant, which is amenable to bacterial bioremediation. NfsA, the major oxygen-insensitive nitroreductase of Escherichia coli, is a flavoprotein that is able to reduce chromate...
10.
Ackerley D, Gonzalez C, Park C, Blake 2nd R, Keyhan M, Matin A
Appl Environ Microbiol
. 2004 Feb;
70(2):873-82.
PMID: 14766567
Cr(VI) (chromate) is a toxic, soluble environmental contaminant. Bacteria can reduce chromate to the insoluble and less toxic Cr(III), and thus chromate bioremediation is of interest. Genetic and protein engineering...